Spyre Therapeutics, Inc.

NasdaqGS:SYRE Stock Report

Market Cap: US$1.4b

Spyre Therapeutics Future Growth

Future criteria checks 0/6

Spyre Therapeutics's revenue and earnings are forecast to decline at 37% and 10.1% per annum respectively while EPS is expected to grow by 1.2% per annum.

Key information

-10.1%

Earnings growth rate

1.2%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate-37.0%
Future return on equityn/a
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

Spyre Therapeutics: Different Name, Same Tune

Dec 12

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Oct 01

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09
Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Earnings and Revenue Growth Forecasts

NasdaqGS:SYRE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-255-228-2006
12/31/20254-229-202-1559
12/31/20242-207-170-1299
9/30/2024N/A-215-151-151N/A
6/30/2024N/A-186-141-156N/A
3/31/20241-364-96-111N/A
12/31/20231-339-85-100N/A
9/30/20231-294-72-87N/A
6/30/20231-273-67-67N/A
3/31/20231-78-72-72N/A
12/31/20222-84-80-80N/A
9/30/20226-85-81-81N/A
6/30/20227-88-83-83N/A
3/31/202220-72-61-60N/A
12/31/202119-66-54-54N/A
9/30/202115-68-53-52N/A
6/30/202114-66-54-52N/A
3/31/2021N/A-80-77-74N/A
12/31/2020N/A-81-80-76N/A
9/30/2020N/A-80-79-75N/A
6/30/2020N/A-83-79-75N/A
3/31/2020N/A-80-74-72N/A
12/31/2019N/A-78-67-66N/A
9/30/2019N/A-72-57-57N/A
6/30/2019N/A-62-48-48N/A
3/31/20192-53-41-41N/A
12/31/20184-44-33-32N/A
9/30/20185-36-31-31N/A
6/30/20187-32N/A-30N/A
3/31/20186-29N/A-27N/A
12/31/20175-27N/A-25N/A
9/30/20175-26N/A-23N/A
6/30/20175-25N/A-22N/A
3/31/20175-23N/A-20N/A
12/31/20165-22N/A-19N/A
9/30/20165-20N/A-15N/A
6/30/20165-17N/A-13N/A
3/31/20167-13N/A-12N/A
12/31/20156-12N/A-11N/A
9/30/20155-11N/A-13N/A
6/30/20153-11N/A-11N/A
3/31/2015N/A-12N/A-8N/A
12/31/2014N/A-10N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYRE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SYRE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SYRE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SYRE's revenue is expected to decline over the next 3 years (-37% per year).

High Growth Revenue: SYRE's revenue is forecast to decline over the next 3 years (-37% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SYRE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:13
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Spyre Therapeutics, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Julian HarrisonBTIG